Home > Journals > Journal of Neurosurgical Sciences > Past Issues > Journal of Neurosurgical Sciences 2021 December;65(6) > Journal of Neurosurgical Sciences 2021 December;65(6):618-25

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Journal of Neurosurgical Sciences 2021 December;65(6):618-25

DOI: 10.23736/S0390-5616.18.04494-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Fluorescent tracers in neurosurgical procedures: a European survey

Francesco ACERBI 1 , Francesco RESTELLI 1, Camilla de LAURENTIS 1, Jacopo FALCO 1, Claudio CAVALLO 1, Morgan BROGGI 1, Julius HÖHNE 2, 3, Karl-Michael SCHEBESCH 2, 3, Marco SCHIARITI 1, Paolo FERROLI 1

1 Department of Neurosurgery, Carlo Besta Neurological Institute IRCCS Foundation, Milan, Italy; 2 Department of Neuropathology, University Hospital of Regensburg, Regensburg, Germany; 3 Department of Neurosurgery, University Hospital of Regensburg, Regensburg, Germany



BACKGROUND: In recent years several techniques have been proposed with the aim of improving tumors visualization and extent of resection and, among them, the use of photosensitive dyes is gaining great interest. Regarding the application of the two most used dyes, 5-aminolevulinic acid (5-ALA) and sodium fluorescein (SF), there is still a lack of shared and established protocols among different centers. The main objective of the present study was to evaluate the current practice of fluorescence-guided techniques in neuro-oncological surgery in Europe.
METHODS: An online questionnaire consisting of 33 questions was completed by 136 European Association of Neurosurgical Societies neurosurgeons. Responses were entered into a database and subsequently analyzed.
RESULTS: Data were analyzed from 136 out of 1476 active European neurosurgeons which had been contacted, with a 9,2% response rate. Based on the data from the questionnaire, Germany was the most responsive country (15% of the total respondents) and the main indication for 5-ALA and SF utilization were high-grade gliomas. 5-ALA was mainly used as defined in Gliolan® datasheet, while SF as off-label technique with a 5 mg/kg dose of injection at the end of patient intubation. Both the dyes were mainly used in adult population, more frequently by neurosurgeons with less-than 20 cases per year expertise. Mean price per patient were 817,6 € and 7,7 € for 5-ALA and SF, respectively.
CONCLUSIONS: 5-ALA acid is still the preferred and more established fluorescent dye used during high-grade gliomas resection, with SF as a gaining-attention, really cheaper and more ductile alternative.


KEY WORDS: Aminolevulinic acid; Fluorescein; Glioma; Survey and questionnaires

top of page